Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were down 3.8% during mid-day trading on Friday . The stock traded as low as $3.61 and last traded at $4.10, with a volume of 237,018 shares traded. The stock had previously closed at $4.26.

Several analysts have issued reports on AUPH shares. Canaccord Genuity set a $10.00 price target on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. HC Wainwright assumed coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They set a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. Finally, Leerink Swann reissued an “outperform” rating and issued a $7.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $7.15.

The firm’s 50-day moving average is $3.21 and its 200 day moving average is $2.77. The company’s market cap is $144.32 million.

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.